Prosecution Insights
Last updated: November 20, 2026
Application No. 18/745,400

PLATFORM FOR GENERATING SAFE CELL THERAPEUTICS

Non-Final OA §DOUBLEPATENT
Filed
Jun 17, 2024
Priority
Aug 07, 2017 — provisional 62/542,133 +3 more
Examiner
KELLY, ROBERT M
Art Unit
1638
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Regents of the University of California
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
5m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
705 granted / 953 resolved
+14.0% vs TC avg
Strong +24% interview lift
Without
With
+24.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
51 currently pending
Career history
991
Total Applications
across all art units

Statute-Specific Performance

§101
4.5%
-35.5% vs TC avg
§103
18.9%
-21.1% vs TC avg
§102
15.9%
-24.1% vs TC avg
§112
43.2%
+3.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 953 resolved cases

Office Action

§DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 21-27 are pending as amended 10/3/24 and are considered herein. Formalities: The drawings of 6/17/24 are accepted. The specification as amended 10/3/24 is accepted. The IDS filings and references therein of 10/15/24 and 7/7/25 have been considered and a signed copy of the IDS forms is provided herewith. Applicant’s priority is noted to be: PNG media_image1.png 80 752 media_image1.png Greyscale Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 21-24 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 10,927,349. Although the claims at issue are not identical, they are not patentably distinct from each other because: Claim 21: patent claim 13 teaches producing a cytoplast encoding a cytokine, comprising providing a cell comprising the nucleus and organelles for protein synthesis and secretion of proteins, mechanically removing the nucleus, to thereby produce the cytoplast comprising the mRNA and organelles, where the cytoplast expresses and secretes the cytokine. Claim 17 teaches further transfecting the cytoplast with an exogenous mRNA encoding a functional polypeptide. Claim 22: Claim 14 teaches density gradient centrifugation for the mechanical removal of the nucleus. Claim 23: Claim 15 teaches cytochalasin B. Claim 24: Claim 16 teaches the same storing, removing, and delivering steps. Claim 25: Claim 17 teaches introduction of an additional mRNA to the cytoplast which is expressed. Claim 26: Claim 18 teaches a chemokine receptor. Claim 27: Claim 18 teaches a therapeutic agent. Thus, in light of the patent, the invention is obvious. The Artisan would do so, and expect success, as it is claimed. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ROBERT M KELLY whose telephone number is (571)272-0729. The examiner can normally be reached M-F: 8a-5p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Tracy Vivlemore can be reached at 571-272-2914. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. ROBERT M. KELLY Examiner Art Unit 1638 /ROBERT M KELLY/Primary Examiner, Art Unit 1638
Read full office action

Prosecution Timeline

Jun 17, 2024
Application Filed
Oct 26, 2026
Non-Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799456
Galectin-9 Specific Binding Agents for Use in Treating Cancer
3y 9m to grant Granted Nov 17, 2026
Patent 12758769
Transdermal Optogenetic Peripheral Nerve Stimulation
3y 11m to grant Granted Oct 13, 2026
Patent 12760330
COMPOSITIONS AND METHODS FOR TREATING CEP290 ASSOCIATED DISEASE
3y 8m to grant Granted Oct 13, 2026
Patent 12747425
EX VIVO PROLIFERATION OF EPITHELIAL CELLS
3y 4m to grant Granted Sep 29, 2026
Patent 12747279
CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF
3y 7m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
98%
With Interview (+24.4%)
2y 10m (~5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 953 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month